PROMETHEGAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Promethegan, and when can generic versions of Promethegan launch?
Promethegan is a drug marketed by Cosette and is included in one NDA.
The generic ingredient in PROMETHEGAN is promethazine hydrochloride. There are twelve drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the promethazine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Promethegan
A generic version of PROMETHEGAN was approved as promethazine hydrochloride by ZYDUS PHARMS USA on November 18th, 2005.
Summary for PROMETHEGAN
See drug prices for PROMETHEGAN
Recent Clinical Trials for PROMETHEGAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Shahid Beheshti University | Phase 3 |
Pharmacology for PROMETHEGAN
| Drug Class | Phenothiazine |
Anatomical Therapeutic Chemical (ATC) Classes for PROMETHEGAN
US Patents and Regulatory Information for PROMETHEGAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cosette | PROMETHEGAN | promethazine hydrochloride | SUPPOSITORY;RECTAL | 087165-001 | Aug 14, 1987 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
